Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00830973 · ClinicalTrials.gov registry record
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
A clinical trial, sponsored by Medco Health Solutions.
- Completed
- Registry status
- 184
- Enrollment target
NCT00830973 is a clinical trial that has completed, run by Medco Health Solutions. The registered enrollment target is 184 participants.
The verdict
NCT00830973 has completed, sponsored by Medco Health Solutions.
- COMPLETED
- Registry status
- 184 participants
- Enrollment target
Study Summary
This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast cancer.
Interventions
- OTHER Poor Metabolism Status Follow Up Therapy Considerations
- OTHER CYP2D6 Inhibiting Drugs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00830973
The ClinicalTrials.gov registry entry for NCT00830973 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medco Health Solutions, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Poor Metabolism Status Follow Up Therapy Considerations is the first listed.
NCT00830973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00830973 about?
NCT00830973 is a clinical study titled "The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer". This study will assess the impact of CYP450 2D6 genotype pharmacogenetic testing and the corresponding prescribing impact for postmenopausal women using tamoxifen in a patient care setting for prevention of recurrent breast cancer.
What is the current status of trial NCT00830973?
This trial is currently completed. The enrollment target is 184 participants. The study started on 2007-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00830973?
The interventions under investigation include: Poor Metabolism Status Follow Up Therapy Considerations (OTHER), CYP2D6 Inhibiting Drugs (OTHER).
Who is sponsoring clinical trial NCT00830973?
This trial is sponsored by Medco Health Solutions, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.